Secretin

Overview

Secretin was discovered in 1902 and is recognized as the first hormone to be identified. It is a gastrointestinal peptide hormone produced in the S cells of the duodenum and jejunum in response to gastric chyme entering the small intestine.

Its primary role is to stimulate the pancreas and liver to release bicarbonate and water, which neutralize the acidic chyme from the stomach. This neutralization ensures the optimal functioning of digestive enzymes and protects the intestinal lining from acid damage.

It also inhibits gastric emptying and reduces gastric acid secretion, allowing time for proper digestion. By regulating the pH balance of the small intestine and supporting water homeostasis, it plays a vital role in digestion and systemic balance.

Chemically, it is a linear peptide with a molecular weight of 3055, derived from a precursor protein called prosecretin. Its amino acid sequence shares similarities with other gastrointestinal peptides such as glucagon, GIP, and VIP.

Symptoms

It itself does not cause direct symptoms, but abnormal secretin function or secretion may lead to manifestations linked to gastrointestinal or pancreatic disorders:

1. Digestive Symptoms:
   1. Persistent abdominal pain
   2. Indigestion or bloating
   3. Diarrhea or altered bowel movements
   4. Symptoms of malabsorption
2. Pancreatic Dysfunction:
   1. Recurrent abdominal discomfort
   2. Weight loss despite a normal diet
   3. Steatorrhea (fatty stools)
3. Associated Conditions:
   1. Zollinger-Ellison Syndrome (ZES), marked by excessive gastric acid secretion
   2. Chronic pancreatitis or cystic fibrosis leading to impaired digestion

These symptoms usually prompt a secretin stimulation test or related evaluations to assess pancreatic function.

Causes

Abnormal levels of secretin or altered responses may be linked to several underlying causes:

1. Physiological Triggers:
   1. Entry of acidified food into the duodenum normally stimulates secretin release.
2. Pathological Causes of Increased Secretin:
   1. Zollinger-Ellison Syndrome (ZES): Characterized by gastrin-secreting tumors leading to excessive acid secretion and increased these levels.
   2. Acidified chyme entering the small intestine stimulates an exaggerated release.
3. Pancreatic Disorders:
   1. Chronic pancreatitis
   2. Cystic fibrosis
   3. Pancreatic duct obstruction or stenosis
   4. Pancreas divisum (failure of embryonic duct fusion)
4. Other Conditions:
   1. Anomalous pancreaticobiliary junction
   2. Post-operative pancreatic dysfunction

Thus, its abnormalities often reflect pancreatic insufficiency or excessive gastric acid production.

Risk Factors

Certain individuals are at higher risk of conditions where these levels or functions may be abnormal:

1. Patients with Pancreatic Disorders:
   1. Those with chronic pancreatitis, cystic fibrosis, or pancreatic cancer.
2. Individuals with Gastrinoma or ZES:
   1. Patients showing symptoms of excessive gastric acid and ulcers.
3. Congenital Anomalies:
   1. Pancreas divisum or anomalous pancreaticobiliary junction.
4. Post-Surgical Patients:
   1. Individuals undergoing pancreatic surgery may need evaluation of the secretin response.
5. Patients with Obstructive Conditions:
   1. Main pancreatic duct stenosis or other obstructions affecting digestive fluid flow.

Prevention

While abnormal secretin levels cannot always be prevented, related complications can be minimized through early detection, testing, and medical management:

1. Diagnostic Testing:
   1. Secretin Stimulation Test: Measures the ability of the pancreas to respond to secretin.
   2. Normal bicarbonate concentration: >80 mmol/L in duodenal aspirates.
   3. Abnormal gastrin response may indicate gastrinomas.
   4. Testing is usually performed alongside imaging (CT, MRI, ERCP).
2. Sample Collection and Handling:
   1. Collect 2 mL of fasting blood in EDTA tubes for plasma secretin estimation.
   2. For stimulation tests, synthetic secretin is administered intravenously, and blood or duodenal aspirates are collected at intervals.
3. Lifestyle and Clinical Care:
   1. Regular monitoring of patients with pancreatic or gastric disorders.
   2. Avoidance of factors that aggravate pancreatic dysfunction, such as alcohol abuse in chronic pancreatitis.
4. Medical Monitoring:
   1. Timely evaluation of digestive symptoms to detect conditions like ZES or pancreatic insufficiency early.
   2. Using endoscopic pancreatic function tests (ePFT) during ERCP for duct assessment.